Amylyx Pharmaceuticals, Inc. (AMLX)
Largest Insider Buys in Sector
AMLX Stock Price History Chart
AMLX Stock Performance
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Amylyx Pharmaceuticals, Inc.
Over the last 12 months, insiders at Amylyx Pharmaceuticals, Inc. have bought $437,194 and sold $784,423 worth of Amylyx Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Amylyx Pharmaceuticals, Inc. have bought $16.69M and sold $12.54M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MILNE GEORGE M JR (director) — $879,200. FRATES JAMES M (Chief Financial Officer) — $304,104. Firestone Karen (director) — $106,590.
The last purchase of 40,000 shares for transaction amount of $101,368 was made by FRATES JAMES M (Chief Financial Officer) on 2024‑09‑12.
List of Insider Buy and Sell Transactions, Amylyx Pharmaceuticals, Inc.
| 2024-12-02 | Sale | Chief Medical Officer | 5,421 0.0078% | $5.54 | $30,007 | -19.64% | ||
| 2024-09-30 | Sale | Co-Chief Executive Officer | 18,589 0.0156% | $3.20 | $59,414 | +54.17% | ||
| 2024-09-30 | Sale | Co-Chief Executive Officer | 18,589 0.0156% | $3.20 | $59,429 | +54.17% | ||
| 2024-09-30 | Sale | Chief Medical Officer | 11,442 0.0096% | $3.20 | $36,559 | +54.17% | ||
| 2024-09-30 | Sale | Chief Legal Officer | 8,709 0.0073% | $3.20 | $27,840 | +54.17% | ||
| 2024-09-12 | Chief Financial Officer | 40,000 0.0267% | $2.53 | $101,368 | +89.16% | |||
| 2024-09-05 | director | 50,000 0.0281% | $2.13 | $106,590 | +105.00% | |||
| 2024-09-03 | director | 100,000 0.0579% | $2.20 | $219,800 | +104.17% | |||
| 2024-05-15 | Sale | Chief Legal Officer | 10,455 0.0052% | $1.88 | $19,654 | +24.73% | ||
| 2024-05-15 | director | 2,250 0.0011% | $1.89 | $4,252 | +24.73% | |||
| 2024-05-14 | director | 2,750 0.0014% | $1.89 | $5,184 | +20.86% | |||
| 2024-03-05 | Sale | Co-Chief Executive Officer | 4,135 0.0204% | $18.73 | $77,440 | -87.88% | ||
| 2024-03-05 | Sale | Co-Chief Executive Officer | 4,135 0.0204% | $18.73 | $77,440 | -87.88% | ||
| 2024-03-05 | Sale | Chief Financial Officer | 1,792 0.0088% | $18.73 | $33,560 | -87.88% | ||
| 2024-03-05 | Sale | Chief Legal Officer | 1,540 0.0076% | $18.73 | $28,841 | -87.88% | ||
| 2024-02-23 | Sale | Chief Legal Officer | 2,838 0.014% | $18.76 | $53,231 | -86.06% | ||
| 2024-01-09 | Sale | Co-Chief Executive Officer | 5,841 0.0251% | $16.33 | $95,372 | -83.29% | ||
| 2024-01-09 | Sale | Co-Chief Executive Officer | 5,841 0.0251% | $16.33 | $95,372 | -83.29% | ||
| 2024-01-09 | Sale | Chief Medical Officer | 2,812 0.0121% | $16.33 | $45,915 | -83.29% | ||
| 2024-01-09 | Sale | Chief Financial Officer | 2,716 0.0117% | $16.33 | $44,347 | -83.29% |
Insider Historical Profitability
| MILNE GEORGE M JR | director | 858571 1.2525% | $4.08 | 2 | 1 | +36.36% |
| FRATES JAMES M | Chief Financial Officer | 233464 0.3406% | $4.08 | 1 | 5 | |
| Firestone Karen | director | 55000 0.0802% | $4.08 | 3 | 0 | <0.0001% |
| Quimi Daphne | director | 5000 0.0073% | $4.08 | 2 | 0 | |
| Morningside Venture Investments Ltd | 10 percent owner | 6997302 10.2079% | $4.08 | 1 | 10 | +23.76% |